Recent 8-K filings for DTIL

• May 27, 2026, 7:30 AM ET other material materiality 0.70 positive item 7.01item 8.01item 9.01

  Precision BioSciences reports PBGENE-HBV eliminates cccDNA in biopsies; pgRNA loss in 100% of patients

  Liver biopsy data show 1-log reduction in cccDNA transcripts after two doses at 0.4 mg/kg; indels inactivate remaining <1%.

• May 5, 2026, 7:59 PM ET earnings materiality 0.70 neutral item 2.02item 9.01 ◈ Earnings Releases

  Precision BioSciences Q1 net loss $18.4M; cash $125.8M; PBGENE-HBV and PBGENE-DMD trials advancing

  Net loss $18.4M ($0.75/share) vs $20.6M loss ($2.21/share) in Q1 2025.

• March 12, 2026, 7:59 PM ET earnings materiality 0.85 positive item 2.02item 9.01

  Precision BioSciences Q4 net income $20.1M, PBGENE-HBV shows antiviral activity, cash runway through 2028

  Q4 net income $20.1M ($1.05 diluted EPS) vs net loss $17.8M YoY; FY net loss $45.7M ($3.56/sh).

• February 11, 2026, 6:59 PM ET regulatory materiality 0.85 positive item 7.01item 2.02item 8.01item 9.01

  FDA clears Precision BioSciences' IND for PBGENE-DMD gene editing therapy for DMD

  FDA Study May Proceed allows initiation of clinical trial site activation for Phase 1/2 FUNCTION-DMD study in ambulatory DMD patients.

• January 13, 2026, 6:59 PM ET other material materiality 0.75 positive item 2.02item 7.01item 8.01item 9.01

  Precision BioSciences reports ~$137M cash, outlines 2026 clinical milestones for HBV and DMD programs

  Preliminary cash ~$137M as of Dec 31, 2025; cash runway expected through 2028.

• November 12, 2025, 6:59 PM ET other material materiality 0.60 neutral item 8.01item 9.01

  Precision BioSciences prices $75M underwritten offering of common stock and warrants

  Offering: 10.8M shares + 1.4M pre-funded warrants at $6.14/$6.139995 per unit; gross proceeds ~$75M.

• November 10, 2025, 6:59 PM ET other material materiality 0.85 positive item 7.01item 8.01item 9.01

  Precision BioSciences reports positive Phase 1 PBGENE-HBV data; first human biopsy evidence of viral gene editing

  Phase 1 ELIMINATE-B trial: 9 patients across 0.2, 0.4, 0.8 mg/kg doses (22 total administrations); no dose-limiting toxicities observed.

• November 3, 2025, 6:59 PM ET earnings materiality 0.70 neutral item 2.02item 9.01

  Precision BioSciences Q3 net loss $21.8M ($1.84/sh); PBGENE-HBV doses Cohort 3, PBGENE-DMD IND on track

  Net loss of $21.8M ($1.84/sh) vs $16.4M ($2.25/sh) in Q3 2024.

• August 7, 2025, 7:59 PM ET earnings materiality 0.80 positive item 2.02item 9.01

  Precision BioSciences Q2 net loss $23.5M; HBV gene editing shows HBsAg reduction in all patients

  Net loss of $23.5M ($2.13 per share) vs net income $32.7M a year ago; revenue less than $0.1M (prior $49.9M on non-cash revenue).

• August 6, 2025, 7:59 PM ET other material materiality 0.85 positive item 7.01item 8.01item 9.01

  Precision BioSciences' PBGENE-HBV shows durable HBsAg reduction in Phase 1; cash runway to H2 2027

  Cohort 1 (0.2 mg/kg): well-tolerated; best HBsAg reductions of 56%, 69%, and 47% across three patients.

• May 15, 2025, 7:59 PM ET earnings materiality 0.70 negative item 2.02item 7.01item 9.01

  Precision BioSciences Q1 net loss $20.6M; revenue drops to <$0.1M; PBGENE-DMD accelerated

  Revenue less than $0.1M vs $17.6M in Q1 2024; net loss of $20.6M ($2.21/share) vs net income $8.6M ($1.70/share) a year ago.

• May 14, 2025, 7:59 PM ET other material materiality 0.70 neutral item 7.01item 9.01

  Precision BioSciences accelerates PBGENE-DMD, plans IND/CTA in 2025; pauses PBGENE-3243

  PBGENE-DMD is a first-in-class in vivo gene editing approach targeting exons 45-55; up to 60% of DMD patients carry mutations in this hotspot region.

• March 26, 2025, 7:59 PM ET earnings materiality 0.80 positive item 2.02item 9.01

  Precision BioSciences FY2024 net income $7.2M; PBGENE-HBV Phase 1 shows HBsAg reduction

  Q4 2024 net loss $17.8M ($2.22/sh) vs $16.3M loss in Q4 2023; FY2024 net income $7.2M vs FY2023 loss $61.3M.

• November 4, 2024, 6:59 PM ET earnings materiality 0.70 negative item 2.02item 9.01

  Precision BioSciences Q3 revenue $0.6M, net loss $16.4M; PBGENE-HBV enters clinic

  Revenue $0.6M down from $13.1M YoY; net loss $16.4M ($2.25/share) vs $8.1M loss in Q3 2023.

• October 24, 2024, 7:59 PM ET regulatory materiality 0.78 positive item 2.02item 7.01item 8.01item 9.01

  Precision BioSciences reports ~$121M cash, gets first CTA approval for PBGENE-HBV in Moldova

  Expected cash, cash equivalents, and restricted cash of ~$121M as of Sept 30, 2024 (preliminary, unaudited).

• September 12, 2024, 7:59 PM ET leadership materiality 0.70 neutral item 5.02item 7.01item 9.01 ◈ executive_change

  Precision BioSciences names Murray Abramson SVP Clinical Development, John Fry as HBV Advisor; CMO List retires

  Alan List, CMO, retiring effective Sept 13, 2024; will transition to clinical consultant at $325/hour and remain on SAB.

• August 1, 2024, 7:59 PM ET earnings materiality 0.65 positive item 2.02item 9.01

  Precision BioSciences Q2 2024 net income $32.7M; cash $123.6M; HBV program on track for IND in 2024

  Net income from continuing ops $32.7M vs loss $11.9M YoY; revenue $49.9M (+$30.1M) from Prevail termination.

• May 13, 2024, 7:59 PM ET earnings materiality 0.70 positive item 2.02item 9.01

  Precision BioSciences Q1 2024 revenue $17.6M, net income $8.6M; cash runway into H2 2026

  Revenue $17.6M (up from $8.8M YoY); net income $8.6M vs loss $25.1M in Q1 2023.

• April 16, 2024, 7:59 PM ET other material materiality 0.85 negative item 1.02item 2.02item 7.01item 9.01 ◈ Material Agreements

  Precision BioSciences loses Lilly/Prevail collaboration; regains DMD, PBGENE-LLY2, PBGENE-LLY3 programs

  Prevail (Lilly sub) terminated collaboration without cause effective July 10, 2024; Precision exercised reversion option to regain programs.

• March 27, 2024, 7:59 PM ET earnings materiality 0.75 neutral item 2.02item 9.01 ◈ Earnings Releases

  Precision BioSciences reports FY 2023 net loss of $61.3M; extends cash runway into H2 2026

  FY 2023 revenue $48.7M (up from $25.1M in 2022); loss from continuing ops $42.5M.

• March 1, 2024, 6:59 PM ET other material materiality 0.75 neutral item 8.01item 9.01

  Precision BioSciences prices $40M public offering of 2.5M shares and warrants at $16/unit

  Offering of 2,500,000 common shares and warrants to purchase another 2,500,000 shares at $16.00 per unit.

• January 19, 2024, 6:59 PM ET other material materiality 0.60 neutral item 5.07 ◈ Shareholder Votes ×2

  Precision BioSciences stockholders approve reverse split; board authorized to set ratio 1-for-10 to 1-for-30

  Approximately 68.34% of common shares represented at special meeting on January 18, 2024.

• January 11, 2024, 6:59 PM ET other material materiality 0.90 positive item 1.01item 2.02item 3.02item 7.01item 9.01 ◈ Material Agreements

  Precision BioSciences licenses azer-cel to TG Therapeutics for $17.5M upfront, up to $288M milestones

  Precision grants TG Therapeutics exclusive license for non-oncology applications of azer-cel, receiving $17.5M in upfront and near-term payments.

Executive changes

Earnings & guidance

Materiality & sentiment trend

Max materiality 0.90 · Median 0.70 · Most common event other_material

14 positive 4 negative 18 neutral

source · DTIL on sec.gov